ZBTB44 exhibited the highest frequency of patient specific recognition and was recognised by antibodies in sera from 66% of PTCL, NOS patients and only 12% of control sera. Here, ZBTB44 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.